LXRX vs. NVAX, OPK, GERN, RGLS, MYGN, ZBIO, EBS, RIGL, XOMA, and VNDA
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs. Its Competitors
Novavax (NASDAQ:NVAX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.
Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax has a net margin of 38.14% compared to Lexicon Pharmaceuticals' net margin of -568.04%. Lexicon Pharmaceuticals' return on equity of -103.16% beat Novavax's return on equity.
53.0% of Novavax shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Novavax presently has a consensus price target of $17.00, indicating a potential upside of 169.84%. Lexicon Pharmaceuticals has a consensus price target of $3.67, indicating a potential upside of 287.72%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Novavax.
Novavax has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
In the previous week, Lexicon Pharmaceuticals had 4 more articles in the media than Novavax. MarketBeat recorded 8 mentions for Lexicon Pharmaceuticals and 4 mentions for Novavax. Lexicon Pharmaceuticals' average media sentiment score of 0.52 beat Novavax's score of 0.36 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Summary
Novavax and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 7/1/2025 by MarketBeat.com Staff
